Quantcast

Latest Anticonvulsant Stories

2014-07-22 08:30:55

LOS ANGELES, July 22, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) Therapy for the treatment of neurological and neuropsychiatric disorders, today announced that enrollment has begun in a pediatric open label study of external trigeminal nerve stimulation (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut Syndrome (LGS). The trial is being conducted at...

2014-07-16 20:23:07

LONDON, July 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability https://www.reportbuyer.com/product/2052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html Epilepsy Therapeutics in Asia Pacific...

2014-07-15 08:28:37

WAYNE, Pa. and PORTO, Portugal, July 15, 2014 /PRNewswire/ -- BIAL, a research based international pharmaceutical company, and moksha8, a leading specialty pharmaceutical company in Latin America, announced today an exclusive license for the commercialization of eslicarbazepine acetate (Zebinix® / (Exalief®) in Brazil and Mexico for the treatment of epilepsy. Epilepsy is one of the most common neurological diseases, affecting 70 million worldwide and up to 5 million people in Latin America...

2014-07-08 08:29:45

European Clinical Data and Mechanism of Action Results Presented LOS ANGELES, July 8, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, today announced top-line summaries of presentations made last week at the 11th European Congress on Epileptology in Stockholm, Sweden, related to the use of external...

2014-06-25 12:29:20

SALT LAKE CITY and TORONTO, June 25, 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules announces today that it has received a research grant from the Ontario Brain Institute for its Lorazepam Spray development. The grant was issued for the purpose to study the administration of a...

2014-06-17 12:28:18

SALT LAKE CITY and TORONTO, June 17, 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules expands on its pharmaceutical research and development plans. EastGate has entered into a working collaboration with Dr. Peter Carlen, leading neurologist at Toronto Western Hospital,...

2014-04-29 16:31:05

USL261 Demonstrates Promising PK, PD and Safety Profiles in Patients with Epilepsy PHILADELPHIA, April 29, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., (Upsher-Smith) today announced that Phase I data for USL261 (investigational intranasal midazolam) in patients with epilepsy were presented at the 66(th)( )Annual American Academy of Neurology (AAN) meeting in Philadelphia. The results demonstrated that USL261 at a single dose of up to 7.5 mg was rapidly absorbed and exhibited a...

2014-04-23 12:30:45

Quest Diagnostics' specialty neurology business unveils 10 new epilepsy diagnostic services, including industry's first clinical multi-analyte test for autoimmune epilepsy MADISON, N.J., April 23, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a suite of new testing services from its Athena Diagnostics specialty neurology business designed to help physicians more reliably and quickly diagnose the...

2014-01-22 12:26:32

$200,000 to be Awarded at 2014 Epilepsy Pipeline Update Conference in San Francisco June 5-7, 2014 LANDOVER, Md., Jan. 22, 2014 /PRNewswire-USNewswire/ -- The Epilepsy Foundation today announced a call for entries for the third annual epilepsy "Shark Tank" competition and is accepting submissions that represent the most innovative ideas in epilepsy and seizure treatment and care. The deadline for submitting a letter of intent is March 14, 2014. The selected finalists will receive...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related